Immunic’s (IMUX) “Outperform” Rating Reiterated at Wedbush

by · The Cerbat Gem

Wedbush restated their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research report released on Thursday,Benzinga reports. The brokerage currently has a $45.00 price objective on the stock.

Other analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Immunic in a report on Thursday. B. Riley Financial cut their price objective on Immunic from $40.00 to $27.00 and set a “buy” rating for the company in a report on Friday, May 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, August 26th. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Finally, Roth Capital reiterated a “buy” rating on shares of Immunic in a research report on Tuesday, September 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $47.25.

View Our Latest Analysis on Immunic

Immunic Price Performance

NASDAQ IMUX opened at $11.42 on Thursday. The company’s 50 day simple moving average is $14.68 and its two-hundred day simple moving average is $13.08. The stock has a market capitalization of $155.77 million, a PE ratio of -2.61 and a beta of 1.41. Immunic has a 1 year low of $5.06 and a 1 year high of $17.43.

Immunic (NASDAQ:IMUX – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.36. On average, research analysts anticipate that Immunic will post -3.71 EPS for the current year.

Hedge Funds Weigh In On Immunic

Institutional investors have recently modified their holdings of the company. Avidity Partners Management LP raised its holdings in shares of Immunic by 42.6% during the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock valued at $7,436,000 after buying an additional 2,000,000 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in Immunic in the fourth quarter worth approximately $2,337,000. Vanguard Group Inc. grew its position in Immunic by 5.3% during the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after acquiring an additional 219,957 shares during the last quarter. Laurion Capital Management LP grew its position in Immunic by 106.3% during the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after acquiring an additional 2,000,000 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Immunic by 544.6% during the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock worth $1,825,000 after acquiring an additional 2,888,829 shares in the last quarter. 51.82% of the stock is currently owned by institutional investors.

Immunic Company Profile

(Get Free Report)

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.

Read More